Search
Champions Oncology Inc
CSBRAdd to Watchlist
4.860USD
+0.140+2.97%
Close 10-26 16:00（ET）
67.65MMarket Cap
LossP/E TTM
Champions Oncology Inc (CSBR) Stock Price Target & Forecast
Target Price
12.000USD+109.42%
CSBR Analyst Recommendation Trends
In the current month, CSBR has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CSBR average Analyst price target in the last month is 12.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
CSBR Analyst Rating for Peer Comparison
Updated: Oct 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Biontech SE
BNTX
4
12
8
0
0
24
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Financial Forecasting
Based on analysts' estimates, CSBR EPS is projected to reach 0.020 in FY2027Q2, following reported EPS of -0.031 in FY2027Q1. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q3
FY2026Q4
FY2027Q1
FY2027Q2
Forecast
0.09
-0.05
-0.01
0.02
Actual
-0.02
-0.05
-0.03
--
Surprise
-122.32%
+4.12%
-206.50%
--
FAQs
What is Champions Oncology Inc's expected revenue for the next quarter?
Champions Oncology Inc's expected revenue is 16.37M.
What is Champions Oncology Inc's price target?
Analysts forecast that Champions Oncology Inc's price target is USD 12.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 12.00.
How have Champions Oncology IncCSBR's recent earnings per share performed?
The market expectation was USD -0.03, while Champions Oncology IncCSBR's earnings per share (EPS) for the previous quarter was USD -0.05. EPS for the next quarter is expected at USD 0.02.